VeriSIM Life is building AI enabled biosimulation models. 
VeriSIM will tackle one of the biggest obstacles of drug development: animal testing for drug development. Animal testing is slow, ethically questionable, and doesn't act as much of a filter: 92% of all drug candidates that pass this preclinical testing never make it to market. 

VeriSIM's solution is to create disease-specific biosimulation models, which allow researchers at pharma companies to model in software how a drug will interact in animals. This will allow researchers to test 1000x more potential candidates in the same unit of time, ensuring that drugs that do make it to (human) clinical trials are far more likely to work, and therefore saving millions in annual costs.

National Science Foundation

Stage Venture Partners

TenOneTen Ventures

Intel Capital

OCA Ventures

Serra Ventures

Loup Ventures

Susa Ventures

Twin Capital Management LLC

Village Global

Colorcon Ventures

Morpheus Ventures

Debiopharm Innovation Fund

VeriSIM Life

Haven't registered yet for our webinar January 31st, "AI and Drug Development: Keeping it Real with Pharma" with Dr. Jo Varshney and Dr. Grazia Rovelli, PhD from Italfarmaco? Save your spot now! bit.ly/3uRH8LE

Don't miss this opportunity to see Dr. Jo Varshney at the Westminster Health Forum where she will be speaking at the conference, "Priorities and next steps for tackling antimicrobial resistance in the UK"! Learn more: https://hubs.li/Q02hv-mK0

Check out this mention of BIOiSIM® in "3 Life Science Trends to look out for in 2024" published by All Med Pro as a summary of predictions to look out for in life science: https://hubs.li/Q02hsfXj0

𝐀𝐝𝐝𝐫𝐞𝐬𝐬𝐢𝐧𝐠 𝐋𝐚𝐫𝐠𝐞 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞𝐬' 𝐀𝐃𝐌𝐄 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞 𝐰𝐢𝐭𝐡 𝐡𝐲𝐛𝐫𝐢𝐝 𝐀𝐈

At VeriSIM Life we empathize with the challenges faced in the journey of drug discovery, particularly when it involves large molecules like proteins, antibodies, and nucleic acids. These molecules, integral to advancing medical treatments, present a unique challenge compared to their smaller counterparts. The intricacy of their structures and interactions within the human body makes traditional high-throughput screening methods, which are effective for small molecules, less suitable. This is because high-throughput techniques struggle to accurately capture the complex behaviors and interactions of large molecules in the diverse and dynamic biological environment. This limitation significantly complicates the understanding of their absorption, distribution, metabolism, and excretion (ADME) properties.

In response to this challenge, VeriSIMLife has innovated a hybrid approach, merging the analytical power of artificial intelligence (AI) with deep scientific knowledge. Our AI techniques, including machine learning and deep learning, are adept at handling the complexities inherent to large molecules such as their higher degree of structural variability, extensive post-translational modifications, and complex 3D conformations. By analyzing extensive datasets, these models uncover patterns and features critical to understanding a molecule's #ADME characteristics.

In a recent client project focused on classifying antibodies based on their magnitude of clearance from the body, VeriSIMLife employed Hybrid AI-driven feature transformation and analysis with #BIOiSIM, focusing on key chemical descriptors and leveraging physiological features. This approach enabled us to identify the most sensitive parameters, leading to a 21% improvement in model accuracy over the existing framework. Our method effectively harnessed factors related to the molecules’ interaction and compatibility within biological systems, demonstrating our proficiency in handling complex molecular data with efficiency and precision.

Our mission is not only to tackle these scientific challenges but also to do so with a deep sense of responsibility and compassion towards the scientific community and the patients who stand to benefit from these therapies. By enhancing our AI-driven approach with mathematical modeling, we provide a more holistic understanding of a molecule's journey through the body. This comprehensive strategy not only accelerates the drug development process but also aligns with our commitment to improving human health. We are dedicated to transforming the landscape of large molecule drug development, ensuring that each step we take brings us closer to delivering effective and life-changing treatments to those in need.

There are still spots left to this thought-provoking webinar on January 31st with Dr. Jo Varshney and Dr. Grazia Rovelli, PhD - don't miss it!

Check out our latest case study in which VeriSIM Life investigated for our client a novel drug combination strategy that combines ADCs with current therapies to enhance their effectiveness in reducing tumor burden. Read more: https://hubs.li/Q02gYLgD0

How do you maintain composure when you know there is a solution, but it is not being implemented? I'd love to hear your thoughts and experiences.

Check out this Q&A with CEO & Founder Dr. Jo Varshney, "AI-Driven Predictive Analytics: Transforming Drug Development," about using AI to transform healthcare without wholesale disruption. https://hubs.li/Q02gDZ9L0

🚀 Explore industry insights in VeriSIM Life's upcoming webinar uncovering the impact of artificial intelligence (#AI) on drug development automation. Cut through the AI hype as they delve into its application in drug discovery, addressing questions about its potential to replace jobs and revolutionize the life sciences and pharmaceutical industry. 

Discover how companies are integrating #artificialintelligence into their strategies and research and development (R&D) workflows for success and competitive advantage. 

Featured speakers:
Jo Varshney
Grazia Rovelli, PhD

🗓️ Save your spot: Wednesday, January 31, 2024 | 11am EST / 4pm GMT / 5pm CET
🔗 Register here: https://buff.ly/48ShiG4 



#DrugDevelopment #DrugDiscovery #Biotech #MachineLearning

A company primarily selling to the pharmaceutical industry, founded in 2019, based in Paris, France

Aqemia

Engaged in research and development in the pharmaceutical sector

Center for Responsible Science

VeriSIM Life is a company dedicated to de-risking drug development through AI-driven, multi-disciplinary quantitative methods that predict patient outcomes. They offer a first-in-class decision engine for discovery and R&D de-risking, and provide insights and risk-sharing collaborations for pharmaceutical companies, biotechs, and academic & research institutions. Their mission is to bring clarity to drug development through computational sciences, aiming to improve success rates and reduce the need for redundant trials and animal testing.

news impact assignment basic	general	Mar 5, 2024 1:46 AM	9e379093
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 1:46 AM	b47709d2
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 5, 2024 1:46 AM	036b669b
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 5, 2024 1:46 AM	2a3c3d8c
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:VERISIMLIFE

VeriSIM Life